Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study-Reference-Cited by-同舟云学术

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

Published:2020-03-16 Issue:1 Volume:35 Page:62-74
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Montesinos Pau^ORCID,Roboz Gail J.,Bulabois Claude-Eric,Subklewe Marion,Platzbecker Uwe,Ofran Yishai,Papayannidis Cristina,Wierzbowska Agnieszka,Shin Ho Jin,Doronin Vadim,Deneberg Stefan,Yeh Su-Peng,Ozcan Mehmet Ali,Knapper Steven,Cortes Jorge,Pollyea Daniel A.^ORCID,Ossenkoppele Gert,Giralt Sergio^ORCID,Döhner Hartmut,Heuser Michael,Xiu Liang,Singh Indrajeet,Huang Fei,Larsen Julie S.,Wei Andrew H.

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-020-0773-5.pdf

Reference21 articles.

1. Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116:4422–9.

2. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

3. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.